Abstract
Due to concern over long term safety of continuous treatment with cyclosporin, the aim of this 1-year study was to assess the effect of intermittent therapy with cyclosporin (Neoral®) on the quality of life of patients suffering from chronic plaque psoriasis. A total of 41 patients with chronic plaque psoriasis (26 male, mean age: 36 years, range: 18–61; duration of psoriasis 17 years, range: 2–31) entered a 9-centre open study in which cyclosporin was taken as an initial dose of 5 mg/kg/daily for a maximum of 12 weeks for up to three cycles. Each patient completed a psoriasis specific QOL measure (Psoriasis Disability Index, PDI) at the beginning and end of each treatment cycle and at the end of study. Clinical parameters including Psoriasis Area and Severity Index (PASI) were measured. The PDI scores showed a significant improvement (p < 0.01) between the beginning and end of all three treatment cycles. The various clinical assessments for each treatment period also showed significant improvement (p < 0.001) for all three cycles. When comparing the last follow-up value to baseline there was a clear indication of relapse, but these scores were still significantly better than at baseline (p < 0.01). Notably, the mean PASI score improved by more than 50% (p < 0.001) between first baseline and end of the study. These findings indicate that a short course of intermittent therapy with cyclosporin in microemulsion formulation, used at starting doses of 5 mg/kg/day, improves QOL of patients with chronic plaque psoriasis. Once again, the applicability and validity of the PDI as a useful QOL tool has been demonstrated.
Similar content being viewed by others
References
Mahrle G, Shultze HJ, Farber L, et al. Low dose short-term cyclosporin versus etretinate in psoriasis. J Am Acad Dermatol 1995; 32: 78-88.
Timonen P, Friend D, Abeywickrama K, et al. Efficacy of low dose cyclosporin A in psoriasis: Results of a dose finding study. Br J Dermatol 1990; 122(Suppl 36): 33-39.
Salek MS, Finlay AY. Cyclosporin improves quality of life in psoriasis — does this matter? Br J Dermatol 1993; 129(Suppl 42): 32-44.
Feldman S. Advances in psoriasis treatment. Dermatol Online J 2000; 6(1): 4.
Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61(Suppl 2): 11-21.
Ho VC, Griffiths CE, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. J Am Acad Dermatol 2001; 44(4): 643-651.
Berth-Jones J, Henderson CA, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre study. Br J Dermatol 1997; 136(4): 527-530.
Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporon pharmacokinetics and variability from a microemulsion formulation — a multicentre investigation in kidney transplant patients. Transplantation 1994; 58: 658-663.
Lowe NJ, Wieder JM. Long-term low-dose cyclosporine therapy for severe psoriasis: Effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710-719.
Bourke JF, Berth-Jones J, Holder J, Graham-Brown RAC. A new microemulsion formulation of cyclosporin (Neoral®) is effective in the treatment of cyclosporin — resistant dermatoses. Br J Dermatol 1996; 134: 777-779.
Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of UK Sickness impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123: 751-756.
Fredriksson T, Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
Kinnear PR, Gray CD. SPSS for Windows Made Simple. Hove: Psychology Press Ltd., 1999.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salek, M., Finlay, A., Lewis, J. et al. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral®). Qual Life Res 13, 91–95 (2004). https://doi.org/10.1023/B:QURE.0000015293.69661.ff
Issue Date:
DOI: https://doi.org/10.1023/B:QURE.0000015293.69661.ff